Lilly Reports Results of Tirzepatide in P-lll SURPASS-1 Monotherapy Trial for Type-2 Diabetes
Shots:
- The P-lll SURPASS-1 study involves assessing Tirzepatide as monothx. (5/10/15 mg) vs PBO in 478 patients in the ratio of (1:1:1:1) with T2D inadequately controlled with diet and exercise alone
- Results: A1C reduction: (-1.75% /-1.71%/-1.69% vs- 0.09%); Weight reduction: 6.3/7.0/7.8kg vs 1.0 kg; percentage of participants achieving A1C <7%: 81.8%/84.5%/ 78.3% vs 23.0%; percentage of participants achieving A1C <5.7%: 30.9% /26.8%/38.4% vs 1.4% respectively
- The highest dose led to A1C reduction of 2.07 % with a reduction in body weight by 9.5 kg (11 %)- 51.7 % of patients achieved an A1C less than 5.7 %
Ref: PRNewswire | Image: Diario AS
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com